key: cord-0873456-otvzabs9 authors: Temiz, Selami Aykut; Abdelmaksoud, Ayman; Wollina, Uwe; Kutlu, Omer; Dursun, Recep; Patil, Anant; Lotti, Torello; Goldust, Mohamad; Vestita, Michelangelo title: Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review date: 2021-11-17 journal: J Cosmet Dermatol DOI: 10.1111/jocd.14613 sha: e8d4753c5596d18b8cb945c5844a6d72d04306e8 doc_id: 873456 cord_uid: otvzabs9 INTRODUCTION: The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute Respiratory Distress Syndrome. The safety profile of these vaccines needs is closely assessed. METHODS: This comprehensive review includes searching the PubMed, EMBASE, and Web of Science databases using the keywords “coronavirus”, “COVID‐19”, “vaccine”, “cutaneous reactions”, “allergic reactions”, and “SARS‐CoV‐2”. Manual searching of reference lists of included articles augmented the research. The research was updated in June 2021. RESULTS: In this narrative review, we tried to investigate and discuss the cutaneous and allergic reactions related to SARS‐CoV‐2 vaccines currently available in the literature. As a result, although COVID‐19 vaccines can be reported to develop allergic and anaphylactic reactions, especially after m‐RNA vaccines, they remain at a low rate, and it is observed that these reactions may develop more frequently, especially in patients with previous allergies and mast cell disorders. Fortunately, these reactions are generally transient, benign, self‐limited. CONCLUSION: Although there is still no definitive evidence, as dermatologists, we must be aware of the possibility of cutaneous reactions, newly diagnosed dermatoses, or exacerbation of existing dermatoses that may develop after the COVID‐19 vaccinations. The pandemic caused by the novel coronavirus disease 2019 has had an unprecedented impact on the overall health and the global economy. Rapidly developed public health strategies tried to control the spread of the disease, but were not enough to reduce the impact of the disease. 1 Vaccination is currently the most dependable strategy to end the pandemic, despite the slower-thanhoped-for rollout, particularly for low-to-middle-income countries, and the uncertain duration of protection they afforded. These vaccines are assumed to be more effective in preventing symptomatic disease, severe disease progression, hospitalization, and to reduce mortality rates for the potentially seasonal SARS-CoV-2 infection. 2 Some countries have approved "digital health passes"/"vaccine passports" as a vehicle for "normal life return." 3 The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS-CoV-2 vaccines. 4 The spike protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to acute respiratory distress syndrome. 5 The vaccines used today virus-related protein-based weakened inactivated SARS-CoV-2 virus vaccines (eg, Sinopharm, Sinovac, and Novavax). 4 Following mass vaccination campaigns related to SARS-CoV-2 vaccines, vaccinerelated reactions have been increasingly reported, despite its benign course in general. The significance of these reactions is still to uncover. The safety profile of these vaccines' needs is closely assessed. In this narrative review, we tried to investigate and discuss the cutaneous and allergic reactions related to SARS-CoV-2 vaccines currently available in the literature. This comprehensive review includes searching the PubMed, EMBASE, and Web of Science databases using the keywords "coronavirus," "COVID-19," "vaccine," "cutaneous reactions," "allergic reactions," and "SARS-CoV-2." Manual searching of reference lists of included articles augmented the research. The research was updated in June 2021 (Table 1 ). The quick improvement of SARS-CoV-2 vaccines and the report of anaphylactic reactions during the early stage of worldwide mass vaccination, especially among those with a history of allergy, has raised safety concerns. Acute allergic reaction symptoms The US Centers for Disease Control and Prevention (CDC) reported 157 reactions in approximately 6 million doses of mRNA vaccine, and only 1 out of 5 reactions were anaphylaxis. Therefore, the incidence of anaphylaxis due to COVID-19 vaccine is very low (5 out of 1 000 000 doses) but at least 5 times higher than reported for other vaccines. 21 In fact, since these mRNA vaccines are the first mRNA vaccines approved for human use, there is limited knowledge about the mechanisms underlying anaphylactic reactions associated with their administration. It has been suggested that the underlying mechanism for anaphylaxis caused by these mRNA vaccines may be related to an IgE-mediated hypersensitivity to polyethylene glycol (PEG), a commonly used additive, which is a rare but increasing cause for anaphylaxis. 22 PEG is an ethylene oxide polymer and can be found in a wide variety of medicines, cosmetics, and food additives. In addition, PEG can cross-react with polysorbate, a nonionic surfactant that can also be found in other vaccines. 23 According to the European Anaphylaxis Registry, only 0.3% of all drug-induced anaphylaxis cases are related to PEG and the cross-reacted allergen polysorbate. 24 In addition to PEG, the mRNA-1273 vaccine also contains tromethamine, which can cause an allergic reaction to gadolinium-based contrast material. Tromethamine can also available in certain healthcare and cosmetic products. 22 The COVID-19 has been associated with certain clinical spectrum of cutaneous signs, including urticarial, maculopapular, vesicular, chilblain-like, livedoid, and vasculitic lesions. The pathophysiology and significance of these signs remain uncertain, despite relatively common. Viral hypersensitivity reactions, over-expression of type I interferon, COVID-19 induced coagulopathy, thrombotic microangiopathy, and direct viral endothelial damage are among the proposed theories. 33 Kutlu et al. 34 Pileri et al. 36 Cohen et al. 43 Akdaş et al. 48 It should be addressed whether SARS-CoV-2 infection plays a role in PR development after COVID-19 vaccination ( Figure 1C ). Those with ongoing deterioration of liver function should be managed in a multidisciplinary approach. López-Valle et al. 54 The authors confirmed that ethical policies of the journal have been adherent to. The data that support the findings of this study are available from the corresponding author upon reasonable request. Global impact on dermatology practice due to the COVID-19 pandemic The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection? Digital Health Passes in the Age of COVID-19: Are "Vaccine Passports" Lawful and Ethical? SARS-CoV-2 Vaccines Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA Anaphylactic reactions to novel mRNA SARS-CoV-2/ COVID-19 vaccines Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? Prolonged anaphylaxis to pfizer coronavirus disease 2019 vaccine: a case report and mechanism of action Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Acute Allergic Reactions to mRNA COVID-19 Vaccines Delayed inflammatory reactions to hyaluronic acid fillers: a literature review and proposed treatment algorithm Hyaluronicacid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination -A case report COVID-19/SARS-CoV-2 virusspike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin IIinduced cutaneous inflammation Global recommendations on COVID-19 vaccines and soft tissue filler reactions: a surveybased investigation in cooperation with the international society for Dermatologic and aesthetic surgery (ISDS) Good tolerance of hyaluronic acid injections during the period of the Covid-19 pandemic: observing a cohort of 1093 patients in a prospective, observational real-life study Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine-United States mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). The Journal of Allergy and Clinical Immunology Anaphylaxis to vaccination and polyethylene glycol (PEG): A perspective from the European Anaphylaxis Registry Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders? Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Anaphylaxis after the covid-19 vaccine in a patient with cholinergic urticaria Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases -practical recommendations. A position statement of ETFAD with external experts Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health Cutaneous manifestation of COVID-19 reporting from Middle-Eastern countries: A point of view! The frequency and characteristics of itching in severe COVID-19 patients: first report Follow-up of dermatological manifestations in non-critical hospitalized patients with COVID-19 pneumonia and their prognostic correlation with disease severity Chilblain lesions after COVID-19 mRNA vaccine Pernio after COVID-19 vaccination BNT162b2 mRNA Covid-19 Vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2 Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases Acral chilblainlike lesions following inactivated SARS-CoV-2 vaccination Recurrence of previous chilblain lesions during the second wave of COVID-19: can we still doubt the correlation with SARS-CoV-2? Leukocytoclastic vasculitis flare following the COVID-19 vaccine Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases A concomitant diagnosis of COVID-19 infection and systemic lupus erythematosus complicated by a macrophage activation syndrome: A new case report Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know Psoriasis flare after influenza vaccination in Covid-19 era: A report of four cases from a single center Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19 Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers COVID arm": a reaction to the Moderna vaccine Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2 Recurrent injectionsite reactions after incorrect subcutaneous administration of a COVID-19 vaccine A flare of preexisting erythema multiforme post BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine COVID-19: a possible trigger for oral lichen planus? Annular lichen planus associated with coronavirus SARS-CoV-2 disease (COVID-19) Lichen planus arising after COVID-19 vaccination COVID-19 "second wave" and vaccines: the dermatologists' perspective Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence? Herpes zoster emergence following mRNA COVID-19 vaccine Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2 Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine Vaccines, adjuvants and autoimmunity Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results COVID-19 vaccine-induced radiation recall phenomenon Heterogeneity in reported skin manifestations of COVID-19 and vaccines Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review